Unicycive Therapeutics, Inc
  • About
    • Our Story
    • Our Focus
    • Our Team
    • Board of Directors
  • Our Science
    • Our Approach
    • Pipeline
    • Oxylanthanum Carbonate (OLC)
    • UNI-494
    • Publications & Press
  • Investors
  • Contact
    • Careers

News

Investors

Investors

  • Overview
  • News
  • Events & Presentations
    • IR Calendar
    • Presentations
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Financial & Stock Info
    • Overview
    • Financial Results
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • Resources
    • Overview
    • Contacts
    • FAQ
    • Email Alerts
Feb 20, 2025 7:00am EST

Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360

Jan 28, 2025 7:00am EST

Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science

Jan 07, 2025 7:00am EST

Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science

Dec 17, 2024 7:00am EST

Unicycive Therapeutics Announces Publication of Oxylanthanum Carbonate (OLC) Positive Bioequivalence Data in Clinical Therapeutics

Nov 21, 2024 7:00am EST

Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference

Nov 13, 2024 7:15am EST

Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update

Nov 11, 2024 7:00am EST

Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Oct 28, 2024 7:03am EDT

Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024

Oct 16, 2024 4:35pm EDT

Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024

Oct 14, 2024 7:03am EDT

Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024

  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
Unicycive Theraputics, Inc

About
Our story
Our focus
Our team
Boards of Directors

Our Science
Our Approach
Therapeutic Pipeline
OLC
UNI-494
Publications & Press

Investors

Contact
Careers

4300 El Camino Real, Suite #210
Los Altos, CA 94022
+1 (650) 351-4495
info@unicycive.com

  • LinkedIn
  • YouTube
  • Facebook
  • Instagram
  • Twitter

Copyright © 2025 Unicycive

Legal Notices and Terms of Use Privacy Policy Ad and Cookie Policy